<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>12389155</identifier>
<setSpec>0210-0010</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>García- Muñozguren, S</dc:author>
<dc:author>Giménez-Roldán, S</dc:author>
<dc:description xml:lang="en">INTRODUCTION. Apomorphine is a D2 dopamine agonist, possibly underused despite its efficacy in situations where other medications have failed or lack of indication for stereotactic surgery. Rapidly effective (between 7 and 10 min) and potency approaching that of levodopa allows apomorphine to reduce reliably severe fluctuations, off period dystonia, biphasic dyskinesias or such symptoms as dysphagia, anismus of micturition difficulties. Unlike other agonists, apomorphine has a modest capacity to induce neuropsychiatric complications. Brief duration of response (&lt;60 min) and the need of subcutaneous administration represent major difficulties in practice. OBJECTIVE and DEVELOPMENT. This review undertake some of the pharmacological properties of this orphan drug , its use in practice, and new pathways of development</dc:description>
<dc:type>English Abstract</dc:type>
<dc:language>es</dc:language>
<dc:date>2002 Oct 1-15 </dc:date>
<dc:title xml:lang="es">Uso de apomorfina en la enfermedad de Parkinson.</dc:title>
<dc:title xml:lang="en">[Use of apomorphine in Parkinson s disease].</dc:title>
<dc:publisher>Revista de neurologia</dc:publisher>
</metadata>
</record>
</pubmed-document>
